Published
March 7, 2024

PR-O-SNAP

icon-benefit
In set up
HomeSubstudies
PR-O-SNAP
  • Current Staphylococcus aureus bacteraemia (SAB) treatment usually involves prolonged courses of exclusively intravenous (IV) beta lactam antibiotics
  • Prolonged IV antibiotic treatment is associated with an increased risk of adverse effects, inconvenience for patients, and high cost when compared to oral antibiotics
  • There is currently no evidence demonstrating superior clinical outcomes with IV administration compared to oral administration.
  • Current studies suggest that co-administration of oral beta-lactam antibiotics with probenecid (PCT therapy) significantly improves drug exposure in serum
  • This study aims to demonstrate the aforementioned effect of PCT in SAB infections, along with its potential as a safe and effective alternative to weeks of IV antibiotic therapy.

This substudy is being conducted in New Zealand.

Lead Investigators:

Dr. Max Bloomfield - Te Whatu Ora - Capital, Coast and Hutt Valley, Wellington Hospital (Maxim.Bloomfield@ccdhb.org.nz)

Dr. Genevieve Walls - Te Whatu Ora - Counties Manukau, Middlemore Hospital (Genevieve.Walls@middlemore.co.nz)

What will the substudy involve - more information
  • Blood samples will be collected during the intravenous and oral phases of each participant's treatment
  • A convenience sampling method will be used where possible (i.e at the same time of other necessary blood tests that are part of the hospital's standard of care)
Risks and benefits of taking part in this sub study

Risks:

  • Blood sample collection involves minimal volume and poses no significant risk to study participants
  • Antibiotic treatment involves some potential adverse events but are outlined as per SNAP core protocol.

Substudies in Progress

SNAP Trial

CERT-SNAP

Combination Cefazolin with Ertapenem for methicillin-susceptible Staphylococcus aureus bacteremia.

icon-benefit
All Interested
icon-benefit
Substudy in Progress

DAPTO-SNAP

Daptomycin vs. Vancomycin for the Treatment of MRSA bacteremia

icon-benefit
All Interested
icon-benefit
Substudy in Progress

SABSI

Profiling the genetic and epigenetic determinants that predispose to severe manifestations of Staphylococcus aureus bacteremia

icon-benefit
All Interested
icon-benefit
Substudy in Progress

cfDNA

Cell-free DNA is a Versatile Analyte to Monitor Complications and Guide Treatment Duration in Staphylococcus aureus Bacteremia

icon-benefit
Any interested
icon-benefit
Substudy in Progress

SABSI-Outcomes

Derivation and Validation of Phenotypes of Staphylococcus aureus bloodstream infection, with Correlation with Outcome.

icon-benefit
Any Interested
icon-benefit
Substudy in Progress

PR-O-SNAP

PK/PD of oral beta-lactam with and without probenecid for treatment of Staphylococcus aureus bacteraemia.

icon-benefit
New Zealand
icon-benefit
Substudy in Progress
BACK TO TOP